Treatment of duodenal ulcer with rioprostil: a randomized multicentre double-blind study.
Scand J Gastroenterol Suppl
; 164: 191-3, 1989.
Article
em En
| MEDLINE
| ID: mdl-2510266
ABSTRACT
The effectiveness of rioprostil, 300 micrograms b.d. is evaluated in evolutive duodenal ulcer in a double-blind study in five French and North African centres. A total of 115 patients are included in the study (57 in the rioprostil group and 58 in the placebo group). After a 4-week treatment period, a significantly higher endoscopic healing rate is observed in the rioprostil group (57%) compared with the placebo group (33%) (p less than 0.01). The mean time with abdominal pain is significantly lower in the rioprostil group (5.6 +/- 4.4 days) compared to the placebo group (12.7 +/- 5 days) (p less than 0.001). Clinical and biological tolerance is excellent. The only side effect is diarrhoea (3.5% in the rioprostil group). In only one case does diarrhoea necessitate cessation of treatment. Rioprostil, 300 micrograms b.d., is thus effective in the treatment of developing duodenal ulcer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Prostaglandinas E
/
Úlcera Duodenal
/
Antiulcerosos
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Scand J Gastroenterol Suppl
Ano de publicação:
1989
Tipo de documento:
Article
País de afiliação:
Argélia